PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsneoplasms
MeSH D009369 - neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009369: 
Neoplasms
21 Companies
21 Drugs
$
Success rate
D003560:Cysts
0 Companies
0 Drugs
Success rate
D006222:Hamartoma
0 Companies
0 Drugs
Success rate
D009370:Neoplasms by histologic type
0 Companies
0 Drugs
Success rate
D009371:Neoplasms by site
0 Companies
0 Drugs
Success rate
D009374:Experimental neoplasms
0 Companies
0 Drugs
Success rate
D009376:Hormone-dependent neoplasms
5 Companies
2 Drugs
$
Success rate
D009378:Multiple primary neoplasms
0 Companies
0 Drugs
Success rate
D009381:Radiation-induced neoplasms
0 Companies
0 Drugs
Success rate
D009385:Neoplastic processes
1 Company
1 Drug
$
Success rate
D009386:Hereditary neoplastic syndromes
0 Companies
0 Drugs
Success rate
D010257:Paraneoplastic syndromes
1 Company
1 Drug
$
Success rate
D011230:Precancerous conditions
0 Companies
0 Drugs
Success rate
D011252:Neoplastic pregnancy complications
0 Companies
0 Drugs
Success rate
D016609:Second primary neoplasms
0 Companies
0 Drugs
Success rate
D017169:Post-traumatic neoplasms
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Accord HealthcarePalonosetron Palonosetron Accord  2016-05-26   
Zoledronic acid Zoledronic Acid Accord  2014-01-16   
AmgenDarbepoetin alfa Aranesp  2001-06-08 $1,362 M Y2023 
Pegfilgrastim Neulasta  2002-08-22 $1,126 M Y2022 
Esteve PharmaceuticalsThiotepa Thiotepa Riemser  2021-03-26   
Helsinn Birex PharmaceuticalsPalonosetron, Netupitant Akynzeo  2015-05-27   
Palonosetron Aloxi  2005-03-22   
HexalEpoetin alfa Epoetin Alfa Hexal  2007-08-27   
Filgrastim Filgrastim Hexal  2009-02-06   
Kyowa KirinFentanyl PecFent  2010-08-31   
Granisetron Sancuso  2012-04-20   
medacZoledronic acid Zoledronic acid medac  2012-08-03   
Merck Sharp & DohmeAprepitant Emend  2003-11-11 $145 M Y2020 
Fosaprepitant Ivemend  2008-01-11   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
72%
473/656
Phase 2
42%
255/604
Phase 3
32%
108/336
Approved: 21Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Amgen
Pegfilgrastim,
Darbepoetin alfa,
Rucaparib,
Benzocaine,
Transplatin,
Rucaparib camsylate,
Albumin,
Antithrombin iii,
Vitamin e,
Imetelstat,
Aglatimagene besadenovec,
Rilotumumab,
Motesanib,
Ganitumab,
Trebananib,
Calcium dobesilate,
AFURESERTIB,
CONATUMUMAB,
OPROZOMIB,
Palifosfamide,
Pamidronic acid,
Retinol,
Amg-404,
Rhuepo
Bristol Myers Squibb
Idecabtagene vicleucel,
Rucaparib,
Transplatin,
Rucaparib camsylate,
Albumin,
Antithrombin iii,
Bempegaldesleukin,
Lucitanib,
Linrodostat,
Tilsotolimod,
Aglatimagene besadenovec,
Etrolizumab,
Galunisertib,
Brivanib alaninate,
Tanespimycin,
Calcium dobesilate,
Regramostim,
Vorhyaluronidase alfa,
Molgramostim,
SOTIGALIMAB,
Serine,
Sodium lactate,
ALVESPIMYCIN,
CABIRALIZUMAB,
EGANELISIB,
Farletuzumab,
LIRILUMAB,
OSUGACESTAT,
PEGDINETANIB,
Retaspimycin,
TROTABRESIB,
ULOCUPLUMAB,
URELUMAB,
Microcrystalline cellulose,
Retinol,
Vipivotide tetraxetan lutetium lu-177,
BMS-906024,
Epofolate,
Com701,
Brivanab
Hexal
Epoetin alfa,
Filgrastim
Kyowa Kirin
Granisetron,
Fentanyl,
Utomilumab,
Tivantinib,
LITRONESIB,
Krn951
Merck Sharp & Dohme
Fosaprepitant,
Aprepitant,
Fosaprepitant dimeglumine,
Sacituzumab,
Rucaparib,
Melarsoprol,
Transplatin,
Histidine,
Fam-trastuzumab deruxtecan-nxki,
Lutetium dotatate lu-177,
Rucaparib camsylate,
Albumin,
Antithrombin iii,
Vitamin e,
Bintrafusp alfa,
Utomilumab,
Sotatercept,
Cobolimab,
Cilmostim,
Feladilimab,
Entinostat,
Epacadostat,
Aglatimagene besadenovec,
Lenograstim,
Tivantinib,
Dinaciclib,
Trebananib,
Preladenant,
Ridaforolimus,
Vicriviroc,
Calcium dobesilate,
Somatostatin,
Regramostim,
Carmellose,
ADAVOSERTIB,
DERAZANTINIB,
ELIMUSERTIB,
INUPADENANT,
MIRANSERTIB,
EFINEPTAKIN ALFA,
Carboxymethylcellulose,
Sodium chloride,
Sodium lactate,
Albinterferon alfa-2b,
BIRINAPANT,
DALOTUZUMAB,
DEFACTINIB,
LETETRESGENE AUTOLEUCEL,
Palifosfamide,
Pexastimogene devacirepvec,
Quavonlimab,
ROBATUMUMAB,
TOZASERTIB,
VACTOSERTIB,
Vibostolimab,
Microcrystalline cellulose,
Retinol,
Mk-4280,
ASTX-660,
Asp1570,
Asp1951,
Flx475,
Mk0731,
Gsk3174998,
Mk6592,
Nc410,
Mk2461,
Fs120,
Pc14586,
Cgx1321,
Enb003,
Mrx0518
Neovii
Catumaxomab
Pfizer
Filgrastim,
Epoetin zeta,
Sacituzumab,
Losartan,
Angiotensin ii,
Rucaparib,
Txa127,
Benzodiazepine,
Transplatin,
Dabigatran,
Fam-trastuzumab deruxtecan-nxki,
Rucaparib camsylate,
Ado-trastuzumab emtansine,
Tbo-filgrastim,
Albumin,
Antithrombin iii,
Vitamin e,
Vitamin k,
Ivuxolimab,
Utomilumab,
Dactolisib,
Cilmostim,
Sasanlimab,
Aglatimagene besadenovec,
Tanezumab,
Lenograstim,
Perifosine,
Figitumumab,
Doconexent,
MIRDAMETINIB,
Serine,
ASCRINVACUMAB,
COFETUZUMAB PELIDOTIN,
Gedatolisib,
Rogaratinib,
Retinol,
Trx518,
Lmwh,
Su014813
Roche
Entrectinib,
Epoetin beta,
Ibandronic acid,
Rucaparib,
Transplatin,
Rucaparib camsylate,
Ado-trastuzumab emtansine,
Albumin,
Antithrombin iii,
Vitamin e,
Ipatasertib,
Inavolisib,
Aglatimagene besadenovec,
Lampalizumab,
Idasanutlin,
Onartuzumab,
Alfacalcidol,
Acenocoumarol,
Imgatuzumab,
Serine,
Albinterferon alfa-2b,
AVUTOMETINIB,
BELVARAFENIB,
CERGUTUZUMAB AMUNALEUKIN,
CIBISATAMAB,
Emactuzumab,
LUMRETUZUMAB,
SELICRELUMAB,
SIMLUKAFUSP ALFA,
VANUCIZUMAB,
Retinol,
CEP-32496,
CKI-27,
Rg1530,
Ro5045337,
Ro7009789,
Ro4987655,
Ro5212054,
Ro6870810,
Ro7247669,
Rg4733,
Ro5126766,
Ro5429083,
Ro5458640,
Ro7300490,
Ro7444973,
Xtx101,
Rg547
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use